Watch PMVP. Know when insiders buy.
One email the day a filing lands. Free.
PMVP
PMV Pharmaceuticals, Inc.
1.33
−0.00 −0.37%
USD · close Sep 25
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
48
WATCH · shorts 48
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $71.1MP/E —DIV YIELD —FCF YIELD -100.25%REV TTM —NET INCOME −$75.2MNET CASH —52W 1.02 – 1.80SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$18.9M | −$18.1M | — | -0.34 | −$14.6M | $0 | −$14.6M | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$19M | −$18M | — | -0.34 | −$19.7M | $0 | −$19.7M | Aug 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$19.2M | −$18M | — | -0.34 | −$17.2M | $15K | −$17.2M | Mar 6 |
| Q3 2025 · Sep 30 | — | — | — | −$22.5M | −$21.1M | — | -0.40 | −$19.8M | −$1K | −$19.8M | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$22.9M | −$21.2M | — | -0.41 | −$18.3M | $11K | −$18.3M | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$21.6M | −$17.4M | — | -0.34 | −$18.3M | $4K | −$18.3M | Aug 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$25.2M | −$23M | — | -0.45 | −$16.7M | $56K | −$16.7M | Mar 6 |
| Q3 2024 · Sep 30 | — | — | — | −$21.9M | −$19.2M | — | -0.37 | −$16.8M | $1K | −$16.8M | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$20.2M | −$1.2M | — | -0.02 | −$1.6M | $4K | −$1.6M | Nov 12 |
| Q1 2024 · Mar 31 | — | — | — | −$18.2M | −$15.3M | — | -0.30 | −$16.2M | $594K | −$16.8M | Nov 12 |
| Q4 2023 · Dec 31derived | — | — | — | −$18.9M | −$15.8M | — | -0.31 | −$12.1M | $197K | −$12.3M | Mar 6 |
| Q3 2023 · Sep 30 | — | — | — | −$19.6M | −$16.6M | — | -0.34 | −$15.7M | $44K | −$15.7M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$86.2M | −$77.7M | — | -1.48 | −$73.6M | $29K | −$73.6M | — | — |
| FY2024 · to Dec 31 | — | — | −$85.4M | −$58.7M | — | -1.14 | −$51.3M | $655K | −$51.9M | — | — |
| FY2023 · to Dec 31 | — | — | −$80.1M | −$69M | — | -1.44 | −$55.7M | $962K | −$56.6M | — | — |
| FY2022 · to Dec 31 | — | — | −$77M | −$73.3M | — | -1.61 | −$63.8M | $8M | −$71.7M | — | — |
| FY2021 · to Dec 31 | — | — | −$58.3M | −$57.8M | — | -1.28 | −$46.6M | $1.3M | −$47.9M | — | — |
| FY2020 · to Dec 31 | — | — | −$34.9M | −$34.4M | — | -2.40 | −$32.7M | $148K | −$32.9M | — | — |
Every number comes from PMV Pharmaceuticals, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.